
In a phase 3 trial, patients with antibody-positive generalized myasthenia gravis receiving inebilizumab experienced greater improvements in MG-ADL and QMG scores versus placebo by week 26. The treatment was well tolerated, with no increase in serious adverse events. Common side effects included headache, cough, and infusion reactions. These findings support CD19+ B cell depletion as an effective treatment approach in MG.
Like
Save
Share